Atlas Trials

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer

Clinical trial NCT04348032 · UNKNOWN

Trial details

NCT number
NCT04348032
Sponsor
Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Platinum-resistant Recurrent Ovarian Cancer
Start date
2018-03-22
Primary completion
2021-01-28
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.